FMP
Concert Pharmaceuticals, Inc.
CNCE
NASDAQ
Inactive Equity
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
8.37 USD
0 (0%)
About
ceo
Dr. Roger D. Tung Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.concertpharma.com
exchange
NASDAQ
Description
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
CIK
0001367920
ISIN
US2060221056
CUSIP
206022105
Address
65 Hayden Avenue
Phone
781 860 0045
Country
US
Employee
64
IPO Date
Feb 13, 2014
Summary
CIK
0001367920
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
206022105
ISIN
US2060221056
Country
US
Price
8.37
Beta
0.52
Volume Avg.
2.54M
Market Cap
401.95M
Shares
-
52-Week
2.72-8.55
DCF
8.94
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-2.64
P/B
-
Website
https://www.concertpharma.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest CNCE News
It looks like there's no news available.
